HistoSonics Wins Europe’s CE Mark for Histotripsy System
5 Articles
5 Articles
MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics today announced that it has received European CE Mark approval for its Edison® System, launching the commercialization of the company's noninvasive histotripsy technology in Europe. This article, Summary: HistoSonics Receives CE Mark, Opening Access Across Europe and Accelerating Global Commercialization of Edison® Histotripsy Platform, is an original content of 01net.
HistoSonics’ Edison Histotripsy System Receives CE Mark Approval
July 13, 2026—HistoSonics announced that it has received approval in Europe for its Edison system, enabling the commercialization of the company’s histotripsy technology in Europe and other markets that recognize the CE Mark. In the United States, the Edison histotripsy system received FDA de novo clearance in October 2023, noted the company. According to the company, the Edison system is a noninvasive, image-guided platform using histotripsy fo…
MINNEAPOLIS--(BUSINESS WIRE)--HistoSonics announced today that it has obtained CE marking in Europe for its Edison® system. The company's non-invasive histotripsy technology is now being marketed in Europe and in other countries where CE marking is recognized. The Edison system is an innovative, non-invasive, image-supported platform intended for the destruction of liver tumors. It enables the destruction of non-operable liver tumors.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
